(IN BRIEF) Sanofi has announced positive phase 2 clinical results for lunsekimig, a novel bispecific therapy targeting key inflammatory pathways in respiratory diseases. The treatment successfully met primary and key secondary endpoints in studies involving moderate-to-severe asthma and chronic rhinosinusitis … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged asthma treatment, atopic dermatitis, biologic therapy, chronic rhinosinusitis with nasal polyps, clinical trials, CRSwNP, drug development, Houman Ashrafian, IL13, lunsekimig, Nanobody VHH, Phase 2 study, respiratory diseases, Sanofi, Sanofi Advances Respiratory Pipeline with Promising Clinical Data for Dual Targeting Lunsekimig Therapy, Sanofi Reports Positive Phase 2 Results for Lunsekimig in Asthma and Respiratory Diseases Development, TSLP
(IN BRIEF) The FDA has awarded orphan drug designation to Sanofi’s riliprubart for the treatment of antibody-mediated rejection in solid organ transplants, highlighting the therapy’s potential in an area lacking approved options. Riliprubart, a humanized IgG4 antibody targeting activated C1s … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Security & Safety, Technology
Tagged Alyssa Johnsen, AMR, antibody-mediated rejection, C1s inhibition, chronic inflammatory demyelinating polyneuropathy, CIDP, ClinicalTrials.gov, complement pathway, FDA, Global Therapeutic Area Development Head, immunology, MOBILIZE, NCT05156710, NCT06290128, NCT06290141, orphan drug designation, Phase 2 study, riliprubart, Sanofi, SAR445088, solid organ transplantation, VITALIZE
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?